Adrenergic receptor system as a pharmacological target in the treatment of epilepsy (Review)

Abstract

Epilepsy is a complex and common neurological disorder characterized by spontaneous and recurrent seizures, affecting ~75 million individuals worldwide. Numerous studies have been conducted to develop new pharmacological drugs for the effective treatment of epilepsy. In recent years, numerous experimental and clinical studies have focused on the role of the adrenergic receptor (AR) system in the regulation of epileptogenesis, seizure susceptibility and convulsions. α₁-ARs (α_1A, α_1B and α_1D), α₂-ARs (α_2A, α_2B and α_2C) and β-ARs (β₁, β₂ and β₃), known to have convulsant or anticonvulsant effects, have been isolated. Norepinephrine (NE), the key endogenous agonist of ARs, is considered to play a crucial role in the pathophysiology of epileptic seizures. However, the effects of NE on different ARs have not been fully elucidated. Although the activation of some AR subtypes produces conflicting results, the activation of α₁, α₂ and β receptor subtypes, in particular, produces anticonvulsant effects. The present review focuses on NE and ARs involved in epileptic seizure formation and discusses therapeutic approaches.

Introduction

Epilepsy is a brain disorder characterized by recurrent seizures, which is diagnosed in 4 to 10 out of every 1,000 individuals in developed countries and affects 75 million individuals worldwide (1-3). The etiology of epileptic disorders is complex and may be of genetic, developmental or acquired origin (4,5). There is a balance between excitatory and inhibitory synaptic mediators [glutamate and gamma-aminobutyric acid (GABA)] in the healthy brain, and a shift of this balance towards excitation is considered the primary cause of epilepsy (6). In addition, serotonergic receptors (7,8), neuroinflammation (9-11), nitric oxide pathway (12) and various ion channels, such as calcium ions (13) may also play a critical role in the mechanism of epilepsy.

There is ample evidence to indicate that the noradrenergic system plays a key role in the regulation of epileptogenesis and convulsions (14,15). Norepinephrine (NE) is generally synthesized and released from noradrenergic nerve endings in the locus coeruleus (LC) (16,17). Abnormal NE secretion causes an increase in tonic/clonic seizures in mice genetically prone to epileptic seizures (18). Although the LC is a small brainstem nucleus, it is the sole source of NE in the neocortex, hippocampus and cerebellum. NE is a potent neuromodulator involved in regulating the excitability of large-scale brain regions. NE concentrations have been reported to increase at seizure onset and decrease during or shortly following the seizure (19).

The inhibition of NE release by gabapentin and pregabalin has an anticonvulsant effect. These drugs exert their effects by binding to the α2δ subunit of voltage-sensitive Ca²⁺ channels. Similarly, gabapentin and pregabalin cause a decrease in NE release through an increase in the extracellular K⁺ concentration (20). In another study, blocking voltage-sensitive Ca²⁺ channels with melatonin exerted an anti-epileptic effect by inhibiting NE release (21). In addition, the density of adrenergic receptors (ARs) in various brain areas decreases during seizures (22,23). NE exerts a pronounced suppressive effect on the development of epileptic seizures. Consistent with this, a decrease in the NE concentration or the administration of AR antagonists causes an increase in the frequency of seizures (24,25). However, there is evidence to suggest that increased NE levels under certain conditions activate seizures, possibly via different ARs (15,26,27). Furthermore, exposure to specific β₂-adrenergic agonist drugs poses a significant risk for epilepsy (28). Conversely, the β-AR antagonist, propranolol, has been shown to reduce pentylenetetrazole (PTZ)-induced tonic/clonic seizures (29).

The hippocampus plays a crucial role in the pathogenesis of epilepsy and the activation of the α_1A-AR increases the inhibitory tone in the CA1 region of the hippocampus (30). Selective α_1A-AR activation increases action potential firing in a subpopulation of hippocampal CA1 interneurons. In response to this, Na⁺ influx is initiated independently of second messenger signaling. In addition, α_1A-AR activation decreases activity due to increased pre-synaptic GABA in CA1 pyramidal cells (30). Furthermore, blockade of the α_1B adrenoceptor subtype exerts both neuroprotective and anti-epileptic effects (31).

The α₂-adrenoceptor subtype has been reported to modulate seizure susceptibility in different seizure patterns. For example, α₂-adrenoceptor agonist, clonidine, has been shown to suppress the development of PTZ-induced seizures (32,33). By contrast, the α₂-adrenoceptor antagonist, yohimbine, has been found to have proconvulsive properties at relatively high doses in the PTZ-induced seizure model (34). Using the α₂-adrenoceptor pathway, lithium chloride exhibits anticonvulsant properties in the PTZ-induced clonic seizure model (35). Adenosine exerts antiepileptic activity in animals by increasing the seizure threshold induced by PTZ through α₂-adrenoceptors (36). The β-AR is distributed in the central nervous system (CNS), particularly in the amygdala (37). The decreased expression of β-AR in the amygdala of epileptic animals leads to facilitating seizures (38).

Evidently, the activation of different ARs leads to complex effects on epileptic seizures that have not yet been fully elucidated. In the present review, the role of the adrenergic system in epilepsy and the therapeutic potential of AR agonists are discussed.

2. Adrenergic receptor types and subtypes

ARs are membrane-bound G protein-coupled receptors (GPCRs) that mediate the peripheral and central effects of NE. ARs are first divided into two major groups: α- and β-ARs (39). In recent years, the development of new pharmacological tools has revealed nine different subtypes of ARs: Three α₁-ARs (α_1A, α_1B and α_1D), three α₂-ARs (α_2A/D, α_2B and α_2C) and three β-ARs (β₁, β₂ and β₃) (40) (Fig. 1).

Figure 1.

The three adrenoceptor subfamilies and their subtypes. G proteins have a heterotrimeric structure consisting of 3 subunits (α, β and γ). The α subunit can bind guanosine diphosphate and guanosine triphosphate. β and γ subunits mediate the attachment of α to the membrane. α₁-, α₂-, and β-ARs mainly couple to Gq, Gi, and Gs proteins, respectively. α_2A-adrenoceptor subtype agonists often exert their effects by binding to Gi proteins. β-adrenoceptors fundamentally bind to Gs proteins. Gs protein receptors are stimulatory, while Gi proteins are inhibitory.

In total, three subtypes of α₁-AR have been identified in the CNS, and α_1A-ARs are the most abundant (~55%) receptor type. The α_1B- (35%) and α_1D (10%) subtype receptors exhibit a lower distribution (41-43). In particular, α₁-ARs are abundantly isolated in neurons of the thalamus and cortex, and in interneurons containing GABA (44). α_1A-AR has a more widespread distribution than α_1B-AR in the entorhinal cortex and amygdala. Of note, α_1A-AR is also detected in the cortex, but not in a homogeneous distribution (41). Both α₁-AR subtypes have been demonstrated in similar cell types, such as neurons, interneurons and progenitors (45,46). Experimental research has demonstrated that α_1A-AR activation by phenylephrine can significantly reduce hyperexcitability in the hippocampal CA1 region via GABA_A receptors (33).

α₂-ARs have been shown to have both presynaptic and postsynaptic functions. The α_2A-AR is the main inhibitory presynaptic receptor that regulates NE release from sympathetic neurons as part of a feedback loop (40,47). However, in some tissues, α_2C-ARs are considered to be inhibitory presynaptic receptors (48). α_2B-ARs are located on postsynaptic cells and mediate the vasoconstrictive effects of catecholamines released from sympathetic nerves (39).

β-ARs are essential components of the sympathetic nervous system and belong to the superfamily of GPCRs (49). Subsequently, adenylate cyclase (AC) activation causes an increase in cAMP, the main modulator of intracellular events (50). β₁-AR subtypes constitute 70-80% of cardiac β-ARs (49). β₂-ARs are mostly found in airway smooth muscle. In addition, β₂-AR are detected in alveolar type II cells, uterine muscle, mast cells, mucous glands, skeletal muscle, epithelial cells and vascular endothelium (51).

β₃-ARs are abundantly found in adipose tissue and participate in the regulation of lipolysis and thermogenesis. It has been shown that some β₃ agonists have anti-stress effects. This suggests that β₃-ARs also play a role in the CNS. Furthermore, β₃-ARs have been found in the urinary bladder, gallbladder and brown adipose tissue (52). β₃-ARs are Gs-type G protein receptors and are involved in norepinephrine-induced AC activation (53).

3. Effects of α₁-adrenergic receptors on epilepsy

Changes in α_1A-AR intensity have been found in animals with seizures (54,55) and in patients with epilepsy (22). α_1A-ARs are usually found in postsynaptic neurons and are activated by NE (56). The activation of these receptors specifically inhibits seizures of the limbic system (57). In general, the activation of α-ARs attenuates the rate of epileptiform discharges (58). α₁-ARs frequently increase the activity of GABAergic interneurons, and GABA released from interneurons plays a key role in the inhibitory effects of these receptors (59,60). By contrast, the overactivity of α_1B-AR causes spontaneous epileptic seizures in mice overexpressing α_1B-AR (61), while a deficiency in α_1B-AR results in the reduction of pilocarpine-induced seizures (31) (Table I) (30,31,62-73).

Table I.

Proconvulsant/anticonvulsant activities of adrenergic receptors.

Receptor subtypes	Compound/expression	Mode of action	Proconvulsant/anti-convulsant	Mechanism of action	(Refs.)
α1A	Phenylephrine	Agonist	Anti-convulsant	Activation of the α1A-AR prompts release of GABA onto CA1 pyramidal cells	(30)
α1	Prazosin	Antagonist	Proconvulsant	α1 receptor blockade	(62)
α1B	Receptor overexpression	-	Proconvulsant	Overexpression of α1B-adrenergic receptor in an animal model of epilepsy	(63)
α1B	Receptor deficiency	-	Anti-convulsant	α1B-adrenergic receptor deficiency in KO mice	(31)
α1	Terazosin	Antagonist	Proconvulsant	Adrenergic α1 AR blockade in PTZ model epilepsy	(64)
α1	Terazosin	Antagonist	Anti-convulsant	It delays seizures caused by acute restraint stress.	(65)
α2	Dexmedetomidine	Agonist	Anti-convulsant	Activation of the α2-AR in PTZ model epilepsy	(66)
α2	Atipamezole	Selective antagonist	Proconvulsant	Prevents post-traumatic epilepsy	(67)
α2	6-Fluoronorepinephrine	Agonist	Anti-convulsant	Inhibits epileptiform activity in the rat hippocampal CA3 region	(68)
α2	Clonidine	Non-selective agonist	Proconvulsant	Clonidine acts on presynaptic autoreceptors to reduce NE release	(69)
α2	Guanfacine	Selective agonist	Anti-convulsant	Guanfacine exerts its anticonvulsant effect on the postsynaptic receptors of NE	(69)
α2	Atipamezole	Selective antagonist	Anti-convulsant	Alters CaMKII and suppresses seizures in rats with genetic absence epilepsy (GAERS)	(70)
α2	Yohimbine	Antagonist	Anti-convulsant	Enhancement of the pentylenetetrazole-induced seizure threshold in mice	(36)
α2	Clonidine	Agonist	Proconvulsant	Inhibited the anticonvulsant effects of N6-cyclohexyl-adenosine	(36)
β	2-Floronoradrenalin (2-FNA)	Selective agonist	Anti-convulsant	Activation of the noradrenergic locus coeruleus system	(71)
β	Propranolol (icv)	Non-selective antagonist	Anti-convulsant	Anticonvulsant effect through central β2-adrenoceptors.	(72)
β	Propranolol (icv)	Non-selective antagonist	Anti-convulsant	Increases the threshold for lidocaine-induced convulsions	(73)

KO, knockout; PTZ, pentylenetetrazole; icv, intracerebroventricular; CaMKII, Ca²⁺/calmodulin dependent protein kinase II; GABA, gamma-aminobutyric acid.

In the prefrontal cortex, α_1B-ARs are also expressed in both glutamatergic pyramidal cells and GABAergic interneurons (74). The stimulation of α₁-ARs depolarizes GABAergic interneurons, resulting in enhanced GABAergic transmission in prefrontal cortex cells (75). In addition, the activation of the α1A-AR subtype by NE also causes the depolarization of hippocampal CA1 interneurons (30). These interneurons are GABAergic and express the neuropeptide somatostatin, and when activated, somatostatin is released to nearby pyramidal neurons. Moreover, the stimulation of α_1A-AR by NE increases the pre-synaptic release of GABA and somatostatin, thereby reducing CA1 pyramidal activity (76). Furthermore, new pyrrolidin-2-one derivatives with affinity for α₁-ARs cause a decrease in seizure susceptibility by exhibiting GABAergic activity (77). In addition, it has been shown that seizures originating from the medial prefrontal cortex and caused by acute stress are induced by NE stimulation of α₁-ARs (65). Electrophysiological recordings have revealed that NE promotes epileptiform activity induction through α_1-AR stimulation in medial prefrontal cortex pyramidal cells. Similarly, α_1D-AR antagonism decreases hippocampal glutamate levels and produces potent anticonvulsant effects (78). By contrast, α_1A-AR stimulation suppresses epileptiform activity in hippocampal interneurons (30).

4. Effects of α₂-adrenergic receptors on epilepsy

α_2A-ARs are widely distributed in various brain regions, and their activation suppresses the epileptiform activity of areas associated with seizure formation, such as the amygdala (79) and hippocampus (59). Different study data have revealed conflicting results regarding the effects of α₂ agonists on epileptic seizures. Some data report proconvulsant (27), while others anticonvulsant effects (66,80). In different areas of the brain, α_2A- and α_2C-ARs function as both pre- and post-synaptic receptors. It exerts the proconvulsant effects of α₂-AR agonists through presynaptic α₂-ARs (81). These agonists reduce NE release in noradrenergic neuron terminals (82). However, the anticonvulsant effect of α₂-ARs occurs as a result of the released NE activating postsynaptic receptors in target neurons (83). There is also evidence to suggest that post-synaptic α_2A-receptors are primarily responsible for the anticonvulsant effect of α₂-adrenoreceptor agonists (59,70). The anticonvulsant mechanism of action of NE is briefly summarized in Fig. 2.

Figure 2.

The proposed mechanism of action of the adrenergic receptor system in epileptic seizures. Increased hippocampal NE levels suppress seizures through the activation of α_2A-AR and β₂-ARs. Hippocampal NE levels are under negative feedback control of α₂-ARs. NE controls hippocampal DA, GABA and Glu levels via β₂-, α_1A- and α₂-ARs, respectively. Activation of β₂-AR by NE increases hippocampal DA levels and suppresses epileptic seizures. Activation of α_1A-AR and postsynaptic α₂-ARs increases GABA levels in interneurons and inhibits seizures. Glu secretion by presynaptic α2-AR is suppressed and produces potent anticonvulsant effects. AR, adrenoceptor; NE, norepinephrine DA, dopamine; GABA, gamma-aminobutyric acid; Glu, glutamate; PLC, phospholipase C; ER, endoplasmic reticulum.

Increasing extracellular hippocampal dopamine and GABA secretions plays a critical role in the anticonvulsant effect of the NE reuptake inhibitor maprotiline. Moreover, the anticonvulsant effect of maprotiline is potentiated by the administration of a selective α₂- and β₂-agonists. On the other hand, α_1D receptor agonists reduce the anticonvulsant effect (78). The α₂-AR selective agonist, dexmedetomidine, exerts anticonvulsant effects on PTZ-induced seizures, whereas the α₂-AR antagonist ATI facilitates epileptic seizures in rats (66). Furthermore, dexmedetomidine significantly reduced the number of c-Fos positive cells in the rat brain (66). However, another study demonstrated a pro-epileptic effect of dexmedetomidine in spike-wave epilepsy in WAG/Rij rats (84). In previous a study on the rat hippocampus, the α2-AR antagonist was implicated in the NE-mediated anti-epileptic effect in the CA3 domain (85). Electrical brain stimulation in the rat hippocampus exerts an inhibitory effect on epileptiform activity via α₁ and α₂ ARs (86,87). Moreover, the α₂-AR agonist, yohimbine, and adenosine provide an additive effect to increase the seizure threshold induced by pentylenetetrazole in mice (36). Experimental evidence has revealed that the specific cannabinoid CB₁ agonist, ACEA, is involved in its anticonvulsant properties by functionally interacting with α₂-adrenoceptors in PTZ-induced seizures in mice (32).

The effects of α₂-AR agonists on epileptic seizure activity vary depending on the dose. Clonidine, an α₂-AR agonist, exerts anticonvulsant effects at high doses, while it is proconvulsant at low doses (88). The difference in this effect may be partly related to the different signaling pathways initiated by the activation of α₂-ARs. The dose of α_2A agonist used and the adenylate cyclase isoform found in different neurons can determine this effect (89).

5. Effects of β-adrenergic receptors on epilepsy

Β-ARs are low affinity receptors for NE and are activated during periods of intense LC activation with a high NE release. The prolonged stimulation of β-ARs leads to a decrease in their sensitivity (90). β-AR is extensively distributed in the amygdala (37). Long-term antidepressant treatment downregulates β-receptors in the amygdala and leads to an increase in epileptic seizures in rats (24). Similarly, reductions in the concentration of β-ARs in the amygdala of epileptic animals may contribute to facilitating seizures (38). The administration of β₂-AR agonists to mice also causes a reduction in PTZ-induced seizures (82). In addition, the β₂-agonist, salbutamol, has been shown to exhibit anti-epileptic activity in maximal electroshock-induced seizures in mice (91).

The role of β-ARs in epileptic seizure susceptibility is largely unclear, and there are conflicting findings in different studies. An increase in seizures may be an expected result in studies using β-AR blockers (92). By contrast, there are different studies demonstrating that β-AR antagonists exert anticonvulsant effects in various animal models of seizures (93,94). The non-selective β-AR antagonist, propranolol, exerts an anticonvulsant effect by blocking the sodium channel rather than its hippocampal effects (95). However, it is stated that a similar mechanism is responsible for the anticonvulsant effect of clenbuterol, which is a β₂-AR agonist (1). Moreover, the stimulation of β₂-ARs reduces limbic seizures by increasing hippocampal dopamine levels (78). The α-receptor antagonist, phentolamine, selectively reduces anticonvulsant effects, while the β-receptor antagonist, timolol, blocks proconvulsant activity (96). These results suggest that there are different mechanisms in seizure formation in various animal models. Nevertheless, these results clearly indicate that β₂-AR activation plays a critical role in the anticonvulsant effect of NE.

6. Adrenergic modulation of GABA and glutamate

NE exerts excitatory and inhibitory effects on neuronal excitability, depending on receptor subtypes and locations. However, there is evidence to suggest that the dominant effect of NE suppresses excitability in a number of brain regions (83,97). It is a known fact that the pathogenesis of epileptic seizures is associated with the hyperexcitability of brain neurons. Therefore, it is important that NE reduces excitability in its anti-epileptic effect. The effect of NE on neuronal excitability may be via modulation of the conductivity of ion channels or indirectly, usually through GABAergic and glutamatergic transmission (83). Evidence has shown that activating the noradrenergic system facilitates the presynaptic release of GABA (68). In addition, GABA induces NE release by activating GABA_A receptors at noradrenergic nerve terminals (98). NE has the ability to alter the excitability of GABAergic cells in certain brain regions (99). For example, the chronic use of certain antidepressant drugs (e.g., citalopram and fluoxetine) that increase NE levels causes the downregulation of ARs and GABA_A receptors (100). This regulation may be one of the possible reasons for the proconvulsant effect of chronic antidepressant therapy. The activation of a1-ARs can cause epileptic seizures by increasing GABAergic transmission in various brain limbic regions, including the hippocampus (101), piriform cortex (100) and amygdala (102). The activation of α₁-ARs through a decrease in potassium conductivity decreases epileptic seizures in the hippocampus by depolarizing inhibitory interneurons (30,101). In a previous study on the medial prefrontal cortex, it was found that the stimulation of α₁-ARs with phenylephrine facilitated GABAergic transmission to pyramidal neurons (75).

Numerous noradrenergic neurons from the LC make synaptic connections with GABAergic interneurons in the basolateral amygdala. Through the activation of α₁-ARs, NE depolarizes GABAergic interneurons in the amygdala and increases GABA transmission. This causes the inhibition of pyramidal glutamatergic cells (103). Stress suppresses NE-mediated GABAergic transmission. Therefore, it is suggested that this is a possible mechanism underlying the increase in stress-induced seizure activity (102). A significant association has been found between the decrease in the density of α₂-ARs in the amygdala of mice and epileptic seizures (64).

There is evidence to suggest strong associations between the adrenergic and glutamatergic systems in the brain. NE secretion also exerts prominent effects on the neuronal excitatory glutamate system (104). NE plays a key role in regulating the sensitivity of specific postsynaptic glutamate receptors (105). It has been stated that ionotropic glutamate receptors play a critical role in the regulation of NE release, and the activation of glutamate receptors reduces NE levels in the rat hippocampus (104). An increase in glutamatergic activity in the entorhinal cortex leads to the induction of seizures. However, the administration of NE blocks seizure activity in this area (105). NE increases epileptiform activity in the hippocampal dentate gyrus (DG) through N-methyl-D-aspartate (NMDA) receptor activation (106). A significant downregulation in β₁-ARs sensitivity in the DG can reduce the stimulating effect of NE and may thus prevent seizures (105). Furthermore, the epileptic seizures observed in transgenic mice overexpressing α_1B-AR are considered to result from an increased NMDA receptor number via α_1B-ARs (107).

7. Conclusion and future perspectives

There is ample evidence to suggest that the endogenous neuromediator, NE, is involved in the modulation of different types of epileptic seizures. Depending on the activated AR subtype and brain region, NE sometimes has an anti-convulsant and sometimes a convulsant effect. In addition, NE may modulate seizures through affecting various neurotransmitter systems, particularly GABA and glutamate, or voltage-gated Ca²⁺ and/or K⁺ channels. The seizure activity control activity of NE may be impaired in some cases of increased susceptibility to seizures, such as exposure to high levels of NE due to stress. The results of various studies demonstrated that abnormal increases or decreases in NE levels in the brain may cause an impairment in NE-related functions, which may contribute to an increased seizure susceptibility. In conclusion, recent data indicate that the activation of α_1-, α_2- and β_2-AR subtypes with selective receptor agonists produces anticonvulsant effects in epileptic seizures. Fully elucidating the effects of AR subtypes on epileptic seizures may be an important target for the pharmacological treatment of epilepsy.

Funding Statement

Funding: No funding was received.

Availability of data and materials

Not applicable.

Author's contributions

The author EO confirms being the sole contributor of this work. EO conceived and designed the study, and wrote and edited the manuscript. EO has read and approved the final manuscript for publication. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The author declares that he has no competing interests.